Glipizide is a second-generation sulfonylurea that can acutely lower the blood glucose level in humans and is typically prescribed to treat type II Diabetes. Its short biological half-life necessitates that it be administered in two or three doses of 2.5 to 10 mg per day and the problem associated with gastrointestinal disturbances, attempts have been made to develop sustained release product. In the present investigation mucoadhesive beads of Glipizide were formulated employing sodium alginate, carbapol 974P and SCMC. The prepared formulations were evaluated for physical parameter,...